Surgical excision without radiation for ductal carcinoma in situ of the breast

12-year results from the ECOG-ACRIN E5194 study

Lawrence J. Solin, Robert Gray, Lorie L. Hughes, William C. Wood, Mary Ann Lowen, Sunil Badve, Frederick L. Baehner, James N. Ingle, Edith A. Perez, Abram Recht, Joseph A. Sparano, Nancy E. Davidson

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Purpose To determine the 12-year risk of developing an ipsilateral breast event (IBE) for women with ducta carcinoma in situ (DCIS) of the breast treated with surgical excision (lumpectomy) without radiation Patients and Methods A prospective clinical trial was performed for women with DCIS who were selected for low-risk clinical and pathologic characteristics. Patients were enrolled onto one of two study cohorts (not randomly assigned): cohort 1: lowor intermediate-grade DCIS, tumor size 2.5 cm or smaller (n = 561); or cohort 2: high-grade DCIS, tumor size 1 cm or smaller (n = 104) Protocol specifications included excision of the DCIS tumor with a minimum negative margin width of at least 3 mm. Tamoxifen (not randomly assigned) was given to 30% of the patients An IBE was defined as local recurrence of DCIS or invasive carcinoma in the treated breast Median follow-up time was 12.3 years Results There were 99 IBEs, of which 51 (52%) were invasive. The IBE and invasive IBE rates increased over time in both cohorts. The 12-year rates of developing an IBE were 14.4% for cohort 1 and 24.6% for cohort 2 (P =.003). The 12-year rates of developing an invasive IBE were 7.5% and 13.4%, respectively (P =.08). On multivariable analysis, study cohort and tumor size were both significantly associated with developing an IBE (P =.009 and P =.03, respectively) Conclusion For patients with DCIS selected for favorable clinical and pathologic characteristics and treated with excision without radiation, the risks of developing an IBE and an invasive IBE increased through 12 years of follow-up, without plateau. These data help inform the treatment decisionmaking process for patients and their physicians.

Original languageEnglish (US)
Pages (from-to)3938-3944
Number of pages7
JournalJournal of Clinical Oncology
Volume33
Issue number33
DOIs
StatePublished - Nov 20 2015

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Breast
Radiation
Carcinoma in Situ
Neoplasms
Cohort Studies
Segmental Mastectomy
Tamoxifen
Clinical Trials
Carcinoma
Physicians
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Surgical excision without radiation for ductal carcinoma in situ of the breast : 12-year results from the ECOG-ACRIN E5194 study. / Solin, Lawrence J.; Gray, Robert; Hughes, Lorie L.; Wood, William C.; Lowen, Mary Ann; Badve, Sunil; Baehner, Frederick L.; Ingle, James N.; Perez, Edith A.; Recht, Abram; Sparano, Joseph A.; Davidson, Nancy E.

In: Journal of Clinical Oncology, Vol. 33, No. 33, 20.11.2015, p. 3938-3944.

Research output: Contribution to journalArticle

Solin, LJ, Gray, R, Hughes, LL, Wood, WC, Lowen, MA, Badve, S, Baehner, FL, Ingle, JN, Perez, EA, Recht, A, Sparano, JA & Davidson, NE 2015, 'Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study', Journal of Clinical Oncology, vol. 33, no. 33, pp. 3938-3944. https://doi.org/10.1200/JCO.2015.60.8588
Solin, Lawrence J. ; Gray, Robert ; Hughes, Lorie L. ; Wood, William C. ; Lowen, Mary Ann ; Badve, Sunil ; Baehner, Frederick L. ; Ingle, James N. ; Perez, Edith A. ; Recht, Abram ; Sparano, Joseph A. ; Davidson, Nancy E. / Surgical excision without radiation for ductal carcinoma in situ of the breast : 12-year results from the ECOG-ACRIN E5194 study. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 33. pp. 3938-3944.
@article{45df184f4ce5483da4388edf50473035,
title = "Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study",
abstract = "Purpose To determine the 12-year risk of developing an ipsilateral breast event (IBE) for women with ducta carcinoma in situ (DCIS) of the breast treated with surgical excision (lumpectomy) without radiation Patients and Methods A prospective clinical trial was performed for women with DCIS who were selected for low-risk clinical and pathologic characteristics. Patients were enrolled onto one of two study cohorts (not randomly assigned): cohort 1: lowor intermediate-grade DCIS, tumor size 2.5 cm or smaller (n = 561); or cohort 2: high-grade DCIS, tumor size 1 cm or smaller (n = 104) Protocol specifications included excision of the DCIS tumor with a minimum negative margin width of at least 3 mm. Tamoxifen (not randomly assigned) was given to 30{\%} of the patients An IBE was defined as local recurrence of DCIS or invasive carcinoma in the treated breast Median follow-up time was 12.3 years Results There were 99 IBEs, of which 51 (52{\%}) were invasive. The IBE and invasive IBE rates increased over time in both cohorts. The 12-year rates of developing an IBE were 14.4{\%} for cohort 1 and 24.6{\%} for cohort 2 (P =.003). The 12-year rates of developing an invasive IBE were 7.5{\%} and 13.4{\%}, respectively (P =.08). On multivariable analysis, study cohort and tumor size were both significantly associated with developing an IBE (P =.009 and P =.03, respectively) Conclusion For patients with DCIS selected for favorable clinical and pathologic characteristics and treated with excision without radiation, the risks of developing an IBE and an invasive IBE increased through 12 years of follow-up, without plateau. These data help inform the treatment decisionmaking process for patients and their physicians.",
author = "Solin, {Lawrence J.} and Robert Gray and Hughes, {Lorie L.} and Wood, {William C.} and Lowen, {Mary Ann} and Sunil Badve and Baehner, {Frederick L.} and Ingle, {James N.} and Perez, {Edith A.} and Abram Recht and Sparano, {Joseph A.} and Davidson, {Nancy E.}",
year = "2015",
month = "11",
day = "20",
doi = "10.1200/JCO.2015.60.8588",
language = "English (US)",
volume = "33",
pages = "3938--3944",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "33",

}

TY - JOUR

T1 - Surgical excision without radiation for ductal carcinoma in situ of the breast

T2 - 12-year results from the ECOG-ACRIN E5194 study

AU - Solin, Lawrence J.

AU - Gray, Robert

AU - Hughes, Lorie L.

AU - Wood, William C.

AU - Lowen, Mary Ann

AU - Badve, Sunil

AU - Baehner, Frederick L.

AU - Ingle, James N.

AU - Perez, Edith A.

AU - Recht, Abram

AU - Sparano, Joseph A.

AU - Davidson, Nancy E.

PY - 2015/11/20

Y1 - 2015/11/20

N2 - Purpose To determine the 12-year risk of developing an ipsilateral breast event (IBE) for women with ducta carcinoma in situ (DCIS) of the breast treated with surgical excision (lumpectomy) without radiation Patients and Methods A prospective clinical trial was performed for women with DCIS who were selected for low-risk clinical and pathologic characteristics. Patients were enrolled onto one of two study cohorts (not randomly assigned): cohort 1: lowor intermediate-grade DCIS, tumor size 2.5 cm or smaller (n = 561); or cohort 2: high-grade DCIS, tumor size 1 cm or smaller (n = 104) Protocol specifications included excision of the DCIS tumor with a minimum negative margin width of at least 3 mm. Tamoxifen (not randomly assigned) was given to 30% of the patients An IBE was defined as local recurrence of DCIS or invasive carcinoma in the treated breast Median follow-up time was 12.3 years Results There were 99 IBEs, of which 51 (52%) were invasive. The IBE and invasive IBE rates increased over time in both cohorts. The 12-year rates of developing an IBE were 14.4% for cohort 1 and 24.6% for cohort 2 (P =.003). The 12-year rates of developing an invasive IBE were 7.5% and 13.4%, respectively (P =.08). On multivariable analysis, study cohort and tumor size were both significantly associated with developing an IBE (P =.009 and P =.03, respectively) Conclusion For patients with DCIS selected for favorable clinical and pathologic characteristics and treated with excision without radiation, the risks of developing an IBE and an invasive IBE increased through 12 years of follow-up, without plateau. These data help inform the treatment decisionmaking process for patients and their physicians.

AB - Purpose To determine the 12-year risk of developing an ipsilateral breast event (IBE) for women with ducta carcinoma in situ (DCIS) of the breast treated with surgical excision (lumpectomy) without radiation Patients and Methods A prospective clinical trial was performed for women with DCIS who were selected for low-risk clinical and pathologic characteristics. Patients were enrolled onto one of two study cohorts (not randomly assigned): cohort 1: lowor intermediate-grade DCIS, tumor size 2.5 cm or smaller (n = 561); or cohort 2: high-grade DCIS, tumor size 1 cm or smaller (n = 104) Protocol specifications included excision of the DCIS tumor with a minimum negative margin width of at least 3 mm. Tamoxifen (not randomly assigned) was given to 30% of the patients An IBE was defined as local recurrence of DCIS or invasive carcinoma in the treated breast Median follow-up time was 12.3 years Results There were 99 IBEs, of which 51 (52%) were invasive. The IBE and invasive IBE rates increased over time in both cohorts. The 12-year rates of developing an IBE were 14.4% for cohort 1 and 24.6% for cohort 2 (P =.003). The 12-year rates of developing an invasive IBE were 7.5% and 13.4%, respectively (P =.08). On multivariable analysis, study cohort and tumor size were both significantly associated with developing an IBE (P =.009 and P =.03, respectively) Conclusion For patients with DCIS selected for favorable clinical and pathologic characteristics and treated with excision without radiation, the risks of developing an IBE and an invasive IBE increased through 12 years of follow-up, without plateau. These data help inform the treatment decisionmaking process for patients and their physicians.

UR - http://www.scopus.com/inward/record.url?scp=84948448538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948448538&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.60.8588

DO - 10.1200/JCO.2015.60.8588

M3 - Article

VL - 33

SP - 3938

EP - 3944

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 33

ER -